XPHOZAH®
(tenapanor) tablets

Join a leading nephrologist for a speaker program about the first and only phosphate absorption inhibitor with a different non-binder mechanism. Learn about its clinical data, safety, practical considerations, patient cases, and more.

Expanding Perspectives in Hyperphosphatemia Treatment: A Different Approach

Presented by:

Samuel A. Kantor, MD
Nevada Kidney Disease & Hypertension Centers
Las Vegas, NV

ASN Kidney Week 2026 Exhibitor Spotlight
Exhibit Hall A Theater 3
Colorado Convention Center, Denver, CO
Friday, October 23, 2026 11:00 AM-11:45 AM MDT

Scan or click to add to calendar

This is a promotional, non-accredited program sponsored by Ardelyx, and no CME/CE credit will be provided. The speaker is a paid consultant of Ardelyx and is presenting on Ardelyx's behalf. This program is intended only for healthcare professionals for whom the program is reasonably relevant to their practice and who are eligible to attend under applicable law and Ardelyx policy. Non-healthcare professionals (i.e., spouses and other guests without an independent professional interest in the program) may not attend. Any meal or transfer of value may be reported as required by applicable law.

INDICATION

XPHOZAH (tenapanor) 30 mg BID is indicated to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

XPHOZAH is contraindicated in:

- Pediatric patients under 6 years of age
- Patients with known or suspected mechanical gastrointestinal obstruction

WARNINGS AND PRECAUTIONS

Diarrhea

Patients may experience severe diarrhea. Treatment with XPHOZAH should be discontinued in patients who develop severe diarrhea.

MOST COMMON ADVERSE REACTIONS

Diarrhea, which occurred in 43-53% of patients, was the only adverse reaction reported in at least 5% of XPHOZAH-treated patients with CKD on dialysis across trials. The majority of diarrhea events in XPHOZAH-treated patients were reported to be mild-to-moderate in severity and resolved over time, or with dose reduction. Diarrhea was typically reported soon after initiation but could occur at any time during treatment with XPHOZAH. Severe diarrhea was reported in 5% of XPHOZAH-treated patients in these trials.

For additional safety information, please see full Prescribing Information available at XPHOZAH.com/PI.

ardelyx®